new IV antibiotic called Zeftera (ceftobiprole) to fight methicillin-resistant Staph aureus (MRSA)

October 2008

Canadians will have a new IV antibiotic called Zeftera (ceftobiprole) to fight methicillin-resistant Staph aureus (MRSA).

Zeftera is an extended-spectrum cephalosporin...some are calling it the "fifth" generation.

It has activity against gram-positive and gram-negative bacteria. But its most unique feature is that it's also effective against MRSA.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

medicines not getting required refrigeration or freezing
Cardiology more reports of rhabdomyolysis in patients taking both simvastatin and amiodarone (Cordarone, etc)
Dyslipidemia whether the combination of simvastatin and ezetimibe (Ezetrol) causes cancer
confusion about the different OTC alcohols
Respiratory & Allergy Now you can use real numbers to explain how risks outweigh benefits when taking antibiotics for most acute respiratory infections
Sleep Disorders Some drugs can worsen obstructive sleep apnea
Antithrombotics changes in warfarin therapy for venous thromboembolism
Antithrombotics Aggrenox or Plavix instead of aspirin to prevent stroke
volunteer help to respond to emergencies at home or abroad
Infectious Diseases questions about the Listeria outbreaks
Infectious Diseases new IV antibiotic called Zeftera (ceftobiprole) to fight methicillin-resistant Staph aureus (MRSA)
Supplements all the choices of calcium pills
Diabetes & Endocrinology Is there any proof that desiccated thyroid (Thyroid) works better than synthetics (Synthroid, etc)
Practice new Canadian diabetes guidelines